Which problem did the experiment address?
The compounds overlap in hormone biology. Their clinical records diverge in the task, the duration and what happened afterward.
Clinical tasks compared
I compare bowel recovery with fat reduction to show how sharply the clinical task changes. A stronger hormone signal would be an inadequate answer to whether abdominal fat stayed lower after treatment ended.
| Compound or pairing | Task tested | Result and follow-up |
|---|---|---|
| Tesamorelin | Excess abdominal fat in adults with HIV | Visceral-fat reduction sustained at -18% over 52 weeks; fat reaccumulated after discontinuation. |
| Ipamorelin | Return to a tolerated meal after bowel resection in adults | Median 25.3 hours versus 32.6 hours with placebo; the trial missed its primary endpoint. Treatment lasted up to seven days. |
| CJC-1295 with ipamorelin | No controlled human outcome trial of the pair | Clinical benefit, combined exposure and long-term safety remain unmeasured. |
| CJC-1295 with DAC alone | Prolonged growth-hormone and IGF-1 secretion in healthy adults | Growth hormone elevated for at least six days; IGF-1 for nine to eleven days after a single study dose. |
These results answer separate questions. They provide no head-to-head ranking of sleep, recovery or fat loss across the three choices.
A treatment effect and a continuing benefit
Tesamorelin’s follow-up makes continued treatment an explicit condition of the benefit. The six-month trial of visceral and liver fat establishes measurable effects in adults receiving HIV treatment. The longer program and discontinuation observations establish that continuing treatment mattered to keeping visceral fat lower.
Ipamorelin’s clinical disappointment concerns a different proposed benefit, bowel recovery. Its healthy-volunteer blood-level study adds useful pharmacology, without answering a long-term clinical question. With the pair, even the first controlled human outcome comparison remains absent.
For me, a solution becomes more useful as its conditions become more explicit. The return of a problem can be one of those conditions, even when the original benefit was real.
An effect can last in blood for days while its relevance to a clinical goal remains untested.
The safety intervals differ
The secretagogue safety review identifies blood sugar as a concern and calls for longer evidence about cancer and mortality. The cardiovascular injury in rats given a different ghrelin-receptor agonist contributes a class-level signal, with no equivalent long-duration ipamorelin safety study to resolve it.
Tesamorelin’s liver-safety review and 52-week clinical observations address parts of its safety record in defined settings. A favorable finding for a particular organ or interval leaves other questions to be studied.
None of this comparison supplies an individual treatment choice. Tesamorelin has approval for one HIV-related indication; neither ipamorelin nor CJC-1295 has an approved human use. All three are prohibited at all times in sport. The individual compound pages carry the longer accounts, and the FAQ addresses proposed combinations.